Guerbet’s Executive Committee now has 10 members:
- David Hale, Chief Executive Officer
- Christine Allard, SVP Public Affairs and Corporate Communications
- Charlotte Bamière, General Counsel & SVP Compliance
- Raoul Bernhardt, SVP Industrial Operations, EHS and Procurement
- Philippe Bourrinet, SVP Development, Medical & Regulatory Affairs and Group Responsible Pharmacist
- Valérie Brissart, SVP Marketing - Diagnostic Imaging
- Jérôme Estampes, Chief Financial Officer and SVP IT and Business Development & Licensing
- François Nicolas, SVP Research, Development, Innovation and AI
- Eva Ohlsson, SVP Human Resources
- Dan Raffi, SVP Commercial Operations
Upcoming events:
Publication of 2023 annual results
March 20th, 2024 after trading
About Guerbet
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022.
For more information, please visit www.guerbet.com.
Contacts:
Guerbet
Jérôme Estampes, Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.com
Christine Allard, Public Affairs and Corporate Communications Director +33.6.30.11.57.82 / christine.allard@guerbet.com
Seitosei.Actifin
Marianne Py, Financial Communications + 33.1.56.88.11.25 / mpy@actifin.fr
Jennifer Jullia, Press +33.1.56.88.11.19 / jjullia@actifin.fr